SRP3076

IL-13 Variant human

recombinant, expressed in E. coli, ≥98% (SDS-PAGE), ≥98% (HPLC), suitable for cell culture

• Synonym(s): interleukin 13
• NACRES: NA.32
• UNSPSC Code: 12352202

Properties

• biological source: human
• recombinant: expressed in E. coli
• assay: ≥98% (HPLC), ≥98% (SDS-PAGE)
• form: lyophilized
• mol wt: 12.6 kDa
• packaging: pkg of 10 μg
• technique(s): cell culture | mammalian: suitable
• impurities: <0.1 EU/μg endotoxin, tested
• color: white to off-white
• UniProt accession no.: P35225
• shipped in: wet ice
• storage temp.: −20°C
• Gene Information: human ... IL13(3596)

Description

General description

IL13 (interleukin 13) is a classic cytokine produced by Th₂ (T-helper) cells. This gene is localized to human chromosome 5q31, and is composed of four exons and three introns.[1]
Recombinant human IL-13 is a 12.5 kDa protein consisting of 114 amino acid residues.

Application

IL-13 variant human has been used for the treatment of THP1 monocytes, along with with IL-4 and phorbol myristate acetate (PMA), to study the ability of SFN (sulforaphane) to induce THP1 differentiation into M2 macrophage cells.

Biochem/physiol Actions

IL13 (interleukin 13) is up-regulated during parasitic infections, and participates in host′s protective immunity against Schistosoma japonicum. This protein promotes eosinophil activation resulting in elevated specific IgE against adult and larval antigens. During acute infection it promotes egg expulsion through increased intestinal contractility. It acts as a liver protective agent where it promotes formation of liver granulomas in a CD4⁺ T cell-mediated manner, which results in liver fibrosis.PMID 26258681 In airway disorders, such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis lung disease, IL13 promotes the formation of airway goblet cells, resulting in excess mucus secretion, which in turn, is regulated by IL13-activated autophagy. In adult subjects with ever-asthma, SNP (single nucleotide polymorphism) rs848 in this gene is linked with symptom severity.

Physical form

Lyophilized from 10 mM Sodium Citrate, pH 4.0.

Preparation Note

Centrifuge the vial prior to opening. Reconstitute in 20 mM Acetic Acid to a concentration of 0.1-0.5 mg/ml. Note: Allow the reconstituted vial to sit at 4°C for at >2 hours before use. Do not vortex. This solution can be stored at 2-8°C for up to 1 week. For extended storage, it is recommended to further dilute in a buffer containing a carrier protein (example 0.1% BSA) and store in working aliquots at -20°C to -80°C.

Other Notes

MSPGPVPPST ALRELIEELV NITQNQKAPL CNGSMVWSIN LTAGMYCAAL ESLINVSGCS AIEKTQRMLS GFCPHKVSAG QFSSLHVRDT KIEVAQFVKD LLLHLKKLFR EGQFN

Safety Information

• Storage Class: 11 - Combustible Solids
• wgk: WGK 3
• flash_point_f: Not applicable
• flash_point_c: Not applicable